Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
PR Newswire•02/10/2026•09:06 ET
2
Key Highlights
- ➤Vanda Pharmaceuticals (VNDA) to present three imsidolimab studies at 2026 EADV Annual Meeting
- ➤Imsidolimab presentations cover neutrophil reduction, immunogenicity, and GPP pustulation improvement
- ➤Regulatory and patent exclusivity for imsidolimab expected to extend into the late 2030s
Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting PR Newswire
WASHINGTON, Oct. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced participation at the European Academy of Dermatology and Venereology (EADV) Annual Meeting, being held in Vienna, Austria, from September 30 through October 3, 2026.
Get started
Create a free account to read the full story.